Morgan Stanley Maintains Equal-Weight on AptarGroup, Lowers Price Target to $126
Morgan Stanley maintains AptarGroup (NYSE:ATR) with a Equal-Weight and lowers the price target from $150 to $126.
AptarGroup Announced its Voluntis Unit and AliveCor Partnered to Advance Management of Atrial Fibrillation for Patients with Cancer
Voluntis, an Aptar Pharma company and leader in digital therapeutics, today announced that it has entered into a partnership agreement with AliveCor, Inc. (AliveCor), a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology.
Wells Fargo Maintains Overweight on AptarGroup, Lowers Price Target to $156
Wells Fargo analyst Gabe Hajde maintains AptarGroup (NYSE:ATR) with a Overweight and lowers the price target from $162 to $156.
Deutsche Bank Maintains Buy on AptarGroup, Lowers Price Target to $145
Deutsche Bank analyst Kyle White maintains AptarGroup (NYSE:ATR) with a Buy and lowers the price target from $148 to $145.
AptarGroup Unit Nanopharm Announced Expansion Plans to Enable Full Services Solutions
Nanopharm Ltd., an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), has announced expansion plans to better support increased customer needs.
Deutsche Bank Maintains Buy on AptarGroup, Lowers Price Target to $148
Deutsche Bank analyst Debbie Jones maintains AptarGroup (NYSE:ATR) with a Buy and lowers the price target from $158 to $148.
AptarGroup: Q3 Earnings Insights
AptarGroup (NYSE:ATR) reported its Q3 earnings results on Thursday, October 28, 2021 at 05:00 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell
• LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.
AptarGroup Highlights First Nasally-Administered Pharmaceutical Treatment For Dry Eye Disease Approved By U.S. FDA With Aptar’s Nasal Pump System
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, today announced that its patented Cartridge Pump System (CPS), designed for the multidose
Baird Maintains Neutral on AptarGroup, Lowers Price Target to $135
Baird analyst Ghansham Panjabi maintains AptarGroup (NYSE:ATR) with a Neutral and lowers the price target from $150 to $135.